GNFT
Price:
$3.67
Market Cap:
$173.53M
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic ...[Read more]
Industry
Biotechnology
IPO Date
2019-03-27
Stock Exchange
NASDAQ
Ticker
GNFT
According to Genfit S.A.’s latest financial reports and current stock price. The company's current Enterprise Value is 179.69M. This represents a change of 44.51% compared to the average of 124.34M of the last 4 quarters.
The mean historical Enterprise Value of Genfit S.A. over the last ten years is 405.30M. The current 179.69M Enterprise Value has changed 4.33% with respect to the historical average. Over the past ten years (40 quarters), GNFT's Enterprise Value was at its highest in in the June 2017 quarter at 814.40M. The Enterprise Value was at its lowest in in the March 2012 quarter at 0.
Average
405.30M
Median
455.39M
Minimum
8.58M
Maximum
745.36M
Discovering the peaks and valleys of Genfit S.A. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.49%
Maximum Annual Enterprise Value = 745.36M
Minimum Annual Increase = -94.95%
Minimum Annual Enterprise Value = 8.58M
Year | Enterprise Value | Change |
---|---|---|
2023 | 168.74M | 23.73% |
2022 | 136.38M | 1.49% |
2021 | 8.58M | -94.95% |
2020 | 169.79M | -69.67% |
2019 | 559.71M | 11.25% |
2018 | 503.10M | -19.38% |
2017 | 624.06M | 53.07% |
2016 | 407.68M | -44.12% |
2015 | 729.62M | -2.11% |
2014 | 745.36M | 382.84% |
The current Enterprise Value of Genfit S.A. (GNFT) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
104.57M
5-year avg
208.64M
10-year avg
405.30M
Genfit S.A.’s Enterprise Value is greater than Cyteir Therapeutics, Inc. (-20511738.00), greater than ERYTECH Pharma S.A. (26.49M), less than Eliem Therapeutics, Inc. (0), greater than HCW Biologics Inc. (26.86M), greater than Molecular Partners AG (107.67M), greater than MediciNova, Inc. (59.45M), greater than Anebulo Pharmaceuticals, Inc. (40.61M), greater than Champions Oncology, Inc. (112.78M), greater than Keros Therapeutics, Inc. (165.48M), less than Janux Therapeutics, Inc. (3.24B), greater than Fennec Pharmaceuticals Inc. (161.56M), less than Edgewise Therapeutics, Inc. (2.76B), less than Harmony Biosciences Holdings, Inc. (1.74B), greater than Aerovate Therapeutics, Inc. (44.50M), greater than Adagene Inc. (11.00M), greater than Acrivon Therapeutics, Inc. Common Stock (154.58M), less than Rezolute, Inc. (247.14M), greater than AN2 Therapeutics, Inc. (7.13M),
Company | Enterprise Value | Market cap |
---|---|---|
-20511738.00 | $108.71M | |
26.49M | $47.38M | |
0 | $342.68M | |
26.86M | $15.05M | |
107.67M | $195.74M | |
59.45M | $101.53M | |
40.61M | $42.01M | |
112.78M | $108.76M | |
165.48M | $676.88M | |
3.24B | $3.24B | |
161.56M | $169.78M | |
2.76B | $2.80B | |
1.74B | $1.94B | |
44.50M | $75.07M | |
11.00M | $85.89M | |
154.58M | $193.98M | |
247.14M | $255.53M | |
7.13M | $40.64M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Genfit S.A. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Genfit S.A. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Genfit S.A.'s Enterprise Value?
What is the highest Enterprise Value for Genfit S.A. (GNFT)?
What is the 3-year average Enterprise Value for Genfit S.A. (GNFT)?
What is the 5-year average Enterprise Value for Genfit S.A. (GNFT)?
How does the current Enterprise Value for Genfit S.A. (GNFT) compare to its historical average?